Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 12Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid, Acute 7Blast Crisis 7Neoplasms 6Leukemia, Myeloid, Accelerated Phase 6Myeloproliferative Disorders 5Carcinoma, Non-Small-Cell Lung 5Neoplasms by Histologic Type 4Leukemia, Myeloid 4Hematologic Diseases 4Bone Marrow Diseases 4Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1

Interventions

Cisplatin 76Radiotherapy 44Cetuximab 40pembrolizumab 39Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 23Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8Blood Specimen Collection 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surveys and Questionnaires 6Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Esophagectomy 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × ponatinib × Clear all
NCT01761747 2014-12-23

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Dana-Farber Cancer Institute

Phase 2/3 Terminated
3 enrolled 9 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡